Interprofessional Webinar Series: This webinar is presented in collaboration with the
Palliative Care in Advanced COPD
National Hospice and Palliative Care Organization.
Funding Disclosure: No commercial funding has been accepted for the activity.
Date and Time: December 14, 2017, 12:30 PM – 1:30 PM ET (Live)
Location: Online at http://www.mjhspalliativeinstitute.org/e-learning/
Speaker Name and Title:
Mona Patel, DO
Associate Program Director of Hospice and Palliative Medicine Fellowship
MJHS Hospice & Palliative Care
Purpose: The purpose of this webinar is to discuss the assessment, management, and prognostication of patients with advanced COPD. This webinar will also discuss the role of palliative care providers in lessening symptom burden using pharmacologic and nonpharmacologic interventions and having goals of care conversations with COPD patients.
Participants will be able to:
- Describe common symptoms associated with advanced COPD
- Discuss some of the challenges with prognostication in this population and review available prognostication tools
- Review the evidence regarding pharmacologic and nonpharmacologic treatment strategies for patients with advanced COPD
COPD is a common condition and its prevalence is growing globally Health care professionals and especially palliative care providers would benefit in knowing how best to optimize its management and lessen disease burden to assist patients in maximizing their quality of life and clarifying goals of care.
Target Audience: palliative care specialists, pain specialists, primary care providers, nurse practitioners, registered nurses, advanced practice nurses, registered nurses with a specialty in palliative care/hospice, pharmacists, allied health professionals, fellows, residents, and medical students.
Criteria for Successful Completion:
1. Attendance at entire session (mandatory for nurses and social workers)
2. Submission of completed evaluation form (mandatory to receive CE/CME credit for MDs, nurses,
3. Successful completion of a posttest; 80% passing grade (mandatory to receive CE credit for social
Continuing Education Credits: 1.0
Continuing Education Accreditation:
Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Hospice and Palliative Care Organization (NHPCO) and MJHS. NHPCO is accredited by the ACCME to provide continuing medical education for physicians.
NHPCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: NHPCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
NHPCO designates this live activity for a maximum of 1.0 contact hour. Nurses should claim only the contact hours commensurate with the extent of their participation in the activity. Accredited status by ANCC refers only to continuing nursing education and does not imply endorsement of any commercial product discussed in conjunction with this activity.
Social Workers: NHPCO is an approved provider of continuing education contact hours by the National Association of Social Workers (Provider #886414158).
This program is Approved by the National Association of Social Workers (Approval #886414158-2909 ) for 1 continuing education contact hour.
MJHS Institute for Innovation in Palliative Care SW CPE is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #0242.
Individual: $25 (includes CME/CE certificate)
Group: $95 + $5 per CME/CE certificate
System Requirements for Computers and Mobile Devices:
Mona Patel, DO, has no financial arrangements or affiliations with any commercial entities whose products, research or services may be discussed in these materials. Any discussion of investigational or unlabeled uses of a product will be identified.
Russell K. Portenoy, MD, Planner, has indicated a relationship with AstraZeneca Pharmaceuticals LP and Tabula Rasa for research support.
No other Planning Committee Member has any disclosures.
Planning Committee Members
Barbara Bouton, MA, FT
Colleen Fleming-Damon, PhDc, APRN-BC, ACHPN-BC, C.T.
Steven R. Gardner, MPA, PAHM
Myra Glajchen, DSW
Jennifer Kennedy, RN, MA, BSN, CHC
Russell K. Portenoy, MD
Karen Richards, PhD, EdS
Judith A. Skretny